Quale sarebbe il prezzo per Aardvark Therapeutics, Inc. Common Stock (AARD)

Il prezzo per Aardvark Therapeutics, Inc. Common Stock (AARD) è $7.22

Qual è la capitalizzazione di mercato per Aardvark Therapeutics, Inc. Common Stock (AARD)

La capitalizzazione di mercato per Aardvark Therapeutics, Inc. Common Stock (AARD) è $158.03M

Aardvark Therapeutics, Inc. Common Stock (AARD) Prezzo e Capitalizzazione di Mercato

Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.

Il prezzo per AARD	Attivo B	Capitalizzazione del mercato a B	Risultati
$235,443 $158.03M	NVDA	$5.152T	+3,260,254.85%
$207,319 $158.03M	AAPL	$4.537T	+2,870,804.34%
$190,483 $158.03M	GOOG	$4.169T	+2,637,657.13%
$166,437 $158.03M	MSFT	$3.642T	+2,304,681.06%
$128,161 $158.03M	AMZN	$2.805T	+1,774,640.94%

Il prezzo per AARD

Attivo B

Capitalizzazione del mercato a B

Risultati

$235,443 $158.03M